CTIS2024-513762-18-00进行中（未招募）1 期
A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination with Bezafibrate in Subjects with Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid - 747-213
Intercept Pharmaceuticals Inc.0 个研究点目标入组 72 人开始时间: 2024年5月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •A definite or probable diagnosis of PBC (consistent with the EASL and the AASLD guidelines [Lindor 2009, EASL 2017]), Qualifying ALP and/or bilirubin liver biochemistry values, Age =18 years, Taking UDCA for at least 12 months (stable dose for =3 months) before Day 1 or no UDCA for 3 months before Day 1
排除标准
- •History or presence of other concomitant liver diseases, Clinical complications of PBC, History or presence of decompensating events, History of or current gallbladder diseases, If female, known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating, Treatment with commercially available OCA or participation in a previous study involving OCA, Note: Other protocol defined Inclusion/Exclusion criteria may apply
研究者
相似试验
进行中（未招募）
1 期
Study to determine if the investigational drug obeticholic acid (also known as OCA) in combination with the investigational drug bezafibrate (BZF), has an effect on Primary Biliary Cholangitis (also known as PBC).Primary Biliary Cholangitis (PBC)MedDRA version: 21.0Level: LLTClassification code 10036680Term: Primary biliary cirrhosisSystem Organ Class: 100000004871EUCTR2018-002575-17-GBIntercept Pharmaceuticals, Inc.75
进行中（未招募）
1 期
Study to determine if the investigational drug obeticholic acid (also known as OCA) in combination with the investigational drug bezafibrate (BZF), has an effect on Primary Biliary Cholangitis (also known as PBC).Primary Biliary Cholangitis (PBC)MedDRA version: 21.0Level: LLTClassification code 10036680Term: Primary biliary cirrhosisSystem Organ Class: 100000004871EUCTR2018-002575-17-HRIntercept Pharmaceuticals, Inc.75
进行中（未招募）
1 期
Study to determine if the investigational drug obeticholic acid (also known as OCA) in combination with the investigational drug bezafibrate (BZF), has an effect on Primary Biliary Cholangitis (also known as Primary Biliary Cirrhosis or PBC).Primary Biliary Cholangitis (PBC)MedDRA version: 21.0Level: LLTClassification code 10036680Term: Primary biliary cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2018-002575-17-BEIntercept Pharmaceuticals, Inc.78
进行中（未招募）
1 期
Study to determine if the investigational drug obeticholic acid (also known as OCA) in combination with the investigational drug bezafibrate (BZF), has an effect on Primary Biliary Cholangitis (also known as Primary Biliary Cirrhosis or PBC).Primary Biliary Cholangitis (PBC)MedDRA version: 21.0Level: LLTClassification code 10036680Term: Primary biliary cirrhosisSystem Organ Class: 100000004871EUCTR2018-002575-17-PLIntercept Pharmaceuticals, Inc.75
进行中（未招募）
1 期
Study to determine if the investigational drug obeticholic acid (also known as OCA) in combination with the investigational drug bezafibrate (BZF), has an effect on Primary Biliary Cholangitis (also known as Primary Biliary Cirrhosis or PBC).Primary Biliary Cholangitis (PBC)MedDRA version: 21.0Level: LLTClassification code 10036680Term: Primary biliary cirrhosisSystem Organ Class: 100000004871EUCTR2018-002575-17-GRIntercept Pharmaceuticals, Inc.78